Physician profile
Jeffrey E Smith
NPI 1427009570
$2,325.80
in general payments reported to CMS, 2019-2025
27 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $31.06 · 2021: $45.71 · 2022: $16.84 · 2023: $670 · 2024: $863 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $237.14 | 2019-2024 | |
| Boston Scientific Corporation | $227.83 | 2024-2025 | Watchman Flx, Watchman |
| E.R. Squibb & Sons, L.L.C. | $196.78 | 2024-2025 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $172.88 | 2023-2024 | Inpefa |
| Amgen INC. | $172.11 | 2023-2024 | Repatha |
| Penumbra, INC. | $159.85 | 2025 | Penumbra System |
| Abiomed | $137.10 | 2023-2024 | Impella |
| Kiniksa Pharmaceuticals, Ltd. | $135.00 | 2023 | Arcalyst |
| Abbott Laboratories | $122.61 | 2025 | Triclip |
| Merck Sharp & Dohme LLC | $120.19 | 2023 | Verquvo |
| Medtronic, INC. | $86.96 | 2021-2024 | Micra |
| Kiniksa Pharmaceuticals International, Plc | $63.52 | 2024 | Arcalyst |
| Philips North America LLC | $62.98 | 2023-2025 | Mcot |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.76 | 2022-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $52.32 | 2019-2024 | Xarelto |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $49.65 | 2023 | |
| Novartis Pharmaceuticals Corporation | $42.72 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.69 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $32.82 | 2021-2025 | Nexletol |
| Pfizer INC. | $32.06 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $29.64 | 2024-2025 | Farxiga |
| Kestra Medical Technology Services, INC. | $18.52 | 2024 | Assure Wcd |
| Romark Laboratories, Lc | $18.34 | 2020 | |
| Bard Peripheral Vascular, INC. | $17.59 | 2021 | |
| Baxter Healthcare | $14.48 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Lantheus Medical Imaging, INC. | $13.54 | 2019 | |
| Irhythm Technologies, INC. | $12.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.